Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
High dose group:routine treatment + MSc (2 x10^6 / kg / time)
Low dose group:routine treatment + MSc (1x10^6 / kg / time)
Sponsors
the First Affiliated Hospital of Xinxiang Medical University
Eligibility
Sex/Gender
All
Age
16 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Male or female patients aged 16-75 years; 2. Willing to sign informed consent; 3. novel coronavirus novel coronavirus is highly novel correlate with the novel coronavirus, based on the standard of suspected cases of new coronavirus infection, real-time fluorescence RT-PCR detection of new coronavirus nucleic acid positive, and sequencing of the virus gene; 4. novel coronavirus pneumonia novel coronavirus infection was diagnosed according to the new coronavirus pneumonia diagnosis and treatment plan (trial version sixth). Severe pneumonia is defined by compliance with any of the following: (1) Dyspnea, RR >=30 times / min; (2) At rest, the oxygen saturation <=93%; (3) PaO2 / FiO2 <=300MMHG (lmmhg = o.133kpa). Pa02 / fi02 should be corrected according to the formula: PaO2 / FiO2 x[atmospheric pressure (mmHg) / 760] The pulmonary imaging showed that the lesions progressed more than 50% within 24-48 hours, and the patients were managed as severe.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Patients with malignant tumor, other serious systemic diseases and psychosis; 3. Patients who have recently or are participating in other clinical trials; 4. There was evidence of drug addiction within one year before the trial; 5. Inability or unwillingness to provide informed consent or comply with test requirements; 6. Combined with HIV, tuberculosis, influenza virus, adenovirus and other respiratory tract infection virus infection; 7. Other conditions judged by the researcher as unsuitable for participating in the clinical study.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| C-reactive protein;Detection of lymphocyte subsets;Procalcitonin;Routine blood test;Chest CT;cytokine;Blood biochemistry; | — |
Countries
China
Contacts
Public ContactDou Qifeng
the First Affiliated Hospital of Xinxiang Medical University
Outcome results
None listed